Vantia Therapeutics

About:

Vantia Therapeutics is a pharmaceutical company developing small molecule drugs for unmet medical needs.

Website: http://www.vantia.com

Twitter/X: vantiathera

Top Investors: Novo Holdings, SV Health Investors, Novo Ventures, MVM Life Science Partners

Description:

Vantia Therapeutics is an emerging pharmaceutical company developing novel, small molecule drugs targeting large areas of unmet medical need. Its strong clinical pipeline includes VA106483 for nocturia and VA111913 for dysmenorrhoea, which directly target indications that together affect many millions of people, are poorly treated and represent billion dollar markets. Vantia's strategy is to develop its proprietary drug candidates through Phase II clinical testing and then commercialise through partnerships. The Company was founded in 2008 and is backed by specialist life science investors Novo A/S, SV Life Sciences and MVM Life Science Partners.

Total Funding Amount:

$6.5M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Chilworth, Hampshire, United Kingdom

Founded Date:

2007-01-01

Contact Email:

info(AT)vantia.com

Founders:

Robert Haigh

Number of Employees:

11-50

Last Funding Date:

2011-07-06

IPO Status:

Private

Industries:

© 2025 bioDAO.ai